Evidence map›Paper›PMID 35565388›Full record

ArticleCancers2022

Semaphorin-3F/Neuropilin-2 Transcriptional Expression as a Predictive Biomarker of Occult Lymph Node Metastases in HNSCC.

Carla Meler-Claramonte, Francesc Xavier Avilés-Jurado, Isabel Vilaseca, Ximena Terra, Paloma Bragado, Gemma Fuster, Xavier León Vintró, Mercedes Camacho

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Transcriptional expression of SLC16A7 as a biomarker of occult lymph node metastases in patients with head and neck squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Carla Meler-ClaramonteDoctoral Programme in Biomedicine, Universitat Rovira i Virgili, 43002 Tarragona, Spain.ORCID 0000-0003-2263-4306
Francesc Xavier Avilés-JuradoIISPV, Institut d'Investigació Sanitària Pere Virgili, 43002 Tarragona, Spain.ORCID 0000-0001-5560-8097
Isabel VilasecaAgència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, 2017-SGR-01581, 08001 Barcelona, Spain.ORCID 0000-0003-4399-5522
Ximena TerraMoBioFood Research Group, Biochemistry and Biotechnology Department, Universitat Rovira i Virgili, 43002 Tarragona, Spain.ORCID 0000-0003-1043-5844
Paloma BragadoDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.
Gemma FusterTissue Repair and Regeneration Laboratory, Department of Biosciences, Faculty of Sciences and Technology, University of Vic, 08500 Vic, Spain.ORCID 0000-0002-4501-2422
Xavier León VintróOtorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.ORCID 0000-0001-6286-630X
Mercedes CamachoGenomics of Complex Diseases, Research Institute Hospital Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain.ORCID 0000-0001-5970-3294
Generalitat de Catalunya · ESHospital de Sant Pau · ESInstitut de Recerca Biomèdica Catalunya Sud · ESUniversidad Complutense de Madrid · ESUniversitat Autònoma de Barcelona · ESUniversitat de Vic - Universitat Central de Catalunya · ESUniversitat Rovira i Virgili · ES

Funding

Asociación Española Contra el Cáncer LABAE18025AVILInstituto de Salud Carlos III FIS PI15/02047Instituto de Salud Carlos III FIS PI18/0844Instituto de Salud Carlos III FIS PI19/01661
6 · The paper itself

Abstract

The expression of the semaphorin-3F (SEMA3F) and neuropilin-2 (NRP2) is involved in the regulation of lymphangiogenesis. The present study analyzes the relationship between the transcriptional expression of the SEMA3F-NRP2 genes and the presence of occult lymph node metastases in patients with cN0 head and neck squamous cell carcinomas. We analyzed the transcriptional expression of SEMA3F and NRP2 in a cohort of 53 patients with cN0 squamous cell carcinoma treated with an elective neck dissection. Occult lymph node metastases were found in 37.7% of the patients. Patients with occult lymph node metastases (cN0/pN+) had significantly lower SEMA3F expression values than patients without lymph node involvement (cN0/pN0). Considering the expression of the SEMA3F-NRP2 genes, patients were classified into two groups according to the risk of occult nodal metastasis: Group 1 (

Indexed as

elective neck dissectionhead and neck squamous cell carcinomaHNSCClymphangiogenesisneuropilin-2occult lymph node metastasessemaphorin-3F

Identifiers

PMID35565388
PMCPMC9100497
OpenAlexW4225255039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.